Sandoz Group AG
SIX:SDZ
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
25.01
40.62
|
Price Target |
|
We'll email you a reminder when the closing price reaches CHF.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one SDZ stock under the Base Case scenario is 43.65 CHF. Compared to the current market price of 40.6 CHF, Sandoz Group AG is Undervalued by 7%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Sandoz Group AG
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for SDZ cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Sandoz Group AG
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Sandoz Group AG, a global leader in generics and biosimilars, operates as a subsidiary of the Swiss pharmaceutical giant Novartis. Established in 1886, Sandoz has a storied history rooted in innovation and a commitment to providing high-quality and affordable medications. The company's mission focuses on improving patient access to essential treatments, making it a critical player in the healthcare landscape. With a diverse portfolio of over 1,000 generic pharmaceuticals and a growing range of biosimilars, Sandoz strategically positions itself to meet the increasing global demand for cost-effective alternatives to brand-name drugs. Its robust research and development efforts ensure that Sand...
Sandoz Group AG, a global leader in generics and biosimilars, operates as a subsidiary of the Swiss pharmaceutical giant Novartis. Established in 1886, Sandoz has a storied history rooted in innovation and a commitment to providing high-quality and affordable medications. The company's mission focuses on improving patient access to essential treatments, making it a critical player in the healthcare landscape. With a diverse portfolio of over 1,000 generic pharmaceuticals and a growing range of biosimilars, Sandoz strategically positions itself to meet the increasing global demand for cost-effective alternatives to brand-name drugs. Its robust research and development efforts ensure that Sandoz remains at the forefront of medicinal advancements, enhancing its competitive edge in an ever-evolving market.
For investors, Sandoz Group AG represents an attractive opportunity, driven by several key factors. The global generics market, valued at hundreds of billions, is projected to grow as healthcare costs rise and countries push for more budget-friendly solutions. Furthermore, Sandoz's exceptional reputation for quality and compliance has made it a trusted name among healthcare providers and patients alike. The company's efforts in biotechnology and its expanding portfolio of biosimilars position it well to capture new market segments, especially as patents for major biologics expire. With a strong foundation, a commitment to innovation, and strategic growth initiatives, Sandoz offers not just stability but also potential for significant long-term returns in the dynamic pharmaceutical industry.
Sandoz Group AG, a part of Novartis, is primarily involved in the pharmaceutical industry, focusing on generic and biosimilar medicines. Here are the core business segments of Sandoz:
-
Generic Pharmaceuticals: This segment offers a wide range of generic drugs that are bioequivalent to branded medications but are typically sold at lower prices. Sandoz focuses on various therapeutic areas, including cardiovascular, central nervous system, and oncology.
-
Biosimilars: Sandoz is a pioneer in the development and commercialization of biosimilars, which are biologic medical products highly similar to already approved reference products. This segment focuses on therapies for complex conditions such as cancer, arthritis, and other autoimmune diseases.
-
OTC (Over-the-Counter) Products: Sandoz also has a portfolio of non-prescription medications that are available to consumers without requiring a doctor’s prescription. This includes health and wellness products.
-
Complex Generics: Sandoz is involved in producing complex generics that may include unique formulations, delivery systems, or require specialized manufacturing processes. These products often cater to niche markets within the pharmaceutical sector.
-
Pharmaceutical Development and Manufacturing: This segment encompasses research and development as well as the manufacturing processes tailored for Sandoz products, ensuring compliance with stringent regulatory standards.
Sandoz emphasizes quality, accessibility, and innovation across these segments in order to enhance patient access to essential medications, which aligns with its overall mission to support healthcare systems worldwide.
Sandoz Group AG, a part of the Novartis Group, is a leader in the generic pharmaceuticals and biosimilars market. Its competitive advantages over rivals can be summarized as follows:
-
Strong R&D Capabilities: Sandoz invests significantly in research and development, particularly in biosimilars, which are becoming increasingly important due to their complex nature. This capability allows them to innovate and bring high-quality products to market faster than many competitors.
-
Established Brand Reputation: As a well-known subsidiary of Novartis, Sandoz benefits from the parent company's strong reputation in the pharmaceutical industry. This trust can influence healthcare providers and payers when choosing between brand-name and generic medications.
-
Diverse Product Portfolio: Sandoz has a broad range of products, including generics, biosimilars, and over-the-counter medications. This diversification helps mitigate risks associated with market fluctuations and patent expirations in any single category.
-
Global Reach and Scale: Sandoz operates in many markets worldwide, allowing them to leverage economies of scale in production and distribution. This global presence enables them to respond quickly to regional demands and regulatory changes, often outpacing smaller competitors.
-
Robust Supply Chain Infrastructure: Sandoz has a well-developed and reliable supply chain network, which allows for cost efficiencies and ensures that products are delivered timely and reliably. This infrastructure is vital in the pharmaceutical sector where regulatory compliance and product availability are critical.
-
Regulatory Expertise: The company has extensive experience navigating complex regulatory environments across different countries. This expertise aids in quicker approval processes compared to competitors who might lack this level of experience.
-
Strategic Partnerships and Alliances: Sandoz often engages in partnerships with other companies and institutions to enhance its product offerings and R&D capabilities. These collaborations can foster innovation and expedite time-to-market for new products.
-
Commitment to Sustainability: The growing emphasis on sustainability in the pharmaceutical sector gives Sandoz an edge, as their efforts in responsible sourcing, manufacturing, and environmental management resonate well with stakeholders concerned about corporate social responsibility.
-
Patient-Centric Programs: Sandoz focuses on patient access and affordability initiatives, which can improve brand loyalty and differentiation from competitors. Their value-added services support healthcare providers and patients, making them a preferred choice.
-
Advanced Manufacturing Technologies: Sandoz utilizes state-of-the-art manufacturing processes and technologies, enabling them to maintain high standards of quality and efficiency, which can lead to cost advantages over rivals.
These unique competitive advantages position Sandoz favorably in the highly competitive pharmaceutical landscape, allowing it to respond effectively to market demands and challenges.
As a professional business analyst considering the Sandoz Group AG, several risks and challenges can be anticipated in the near future:
-
Regulatory Changes: The pharmaceutical industry is heavily regulated, and changes in regulations can pose challenges. This includes stricter compliance requirements, changes in pricing regulations, and new health policies that could affect market access.
-
Market Competition: The generic and biosimilars segment faces intense competition from both established companies and new entrants. The pressure to maintain market share while continuously innovating can lead to pricing wars and reduced margins.
-
Product Approval Delays: Delays in obtaining approvals for new products can significantly impact revenue projections. If Sandoz faces challenges with regulatory bodies, it could result in delayed launches and lost market opportunities.
-
Intellectual Property Issues: The pharmaceutical sector is particularly sensitive to patent expirations and patent litigation. Sandoz may face challenges related to defending its generic products against patent claims from branded drug manufacturers.
-
Supply Chain Disruptions: Like many industries, the pharmaceutical sector is vulnerable to supply chain disruptions caused by geopolitical tensions, natural disasters, or pandemics. Such disruptions can affect the availability of raw materials and impact production.
-
Pricing Pressures: There is continuous pressure from governments and payers to lower drug prices. Sandoz might face challenges in maintaining profitability while complying with these pressures.
-
Technological Advancements: Rapid advancements in technology may lead to the emergence of novel treatments that could make existing medications obsolete. Sandoz will need to invest continually in innovation to stay relevant.
-
Global Economic Conditions: Macroeconomic factors, including inflation, exchange rate fluctuations, and economic downturns, can affect revenue and costs. Sandoz must navigate these external economic pressures effectively.
-
Public Perception and Trust: As the availability of generics and biosimilars increases, maintaining a strong reputation and addressing any public concerns about drug efficacy and safety will be crucial. Missteps can lead to reputational damage and affect sales.
-
Shifts in Healthcare Delivery Models: The trend towards personalized medicine and digital health may alter the landscape of pharmaceutical sales and distribution. Sandoz will need to adapt its business model to align with these shifts.
By addressing these risks proactively, Sandoz can position itself for continued success in the increasingly competitive landscape of the pharmaceutical industry.
Revenue & Expenses Breakdown
Sandoz Group AG
Balance Sheet Decomposition
Sandoz Group AG
Sandoz Group AG
Earnings Waterfall
Sandoz Group AG
Revenue
|
10B
USD
|
Cost of Revenue
|
-5.3B
USD
|
Gross Profit
|
4.7B
USD
|
Operating Expenses
|
-3.4B
USD
|
Operating Income
|
1.3B
USD
|
Other Expenses
|
-1.2B
USD
|
Net Income
|
77m
USD
|
Free Cash Flow Analysis
Sandoz Group AG
USD | |
Free Cash Flow | USD |
Sandoz concluded an exceptional 2023, with sales growth surpassing expectations and core EBITDA meeting predictions. Successful spin-off and strategic movements, including key acquisitions and product launches, positioned the company strongly going into 2024. Biosimilar sales rose to 23% of total sales, driving up margins. Full year sales reached $9.6 billion, marking a 7% rise. However, core EBITDA margin saw a 3.2 percentage point dip to 18.1%. The company maintains a robust European presence and has growing momentum in North America and International markets.
What is Earnings Call?
SDZ Profitability Score
Profitability Due Diligence
Sandoz Group AG's profitability score is 54/100. The higher the profitability score, the more profitable the company is.
Score
Sandoz Group AG's profitability score is 54/100. The higher the profitability score, the more profitable the company is.
SDZ Solvency Score
Solvency Due Diligence
Sandoz Group AG's solvency score is 45/100. The higher the solvency score, the more solvent the company is.
Score
Sandoz Group AG's solvency score is 45/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SDZ Price Targets Summary
Sandoz Group AG
According to Wall Street analysts, the average 1-year price target for SDZ is 42.33 CHF with a low forecast of 35.35 CHF and a high forecast of 52.5 CHF.
Dividends
Current shareholder yield for SDZ is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
SDZ Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Sandoz Group AG is a CH-based company operating in Pharmaceuticals industry. The company is headquartered in Rotkreuz, Zug. The company went IPO on 2023-10-04. Sandoz Group AG is a Switzerland based company working in the healthcare technology field, the Company does this by operating in two segments, generics and biosimilar. Generic refers to drugs that is structurally equivalent to an original drug whose patent expired. Biosimilar refers to drugs, unlike generics that are equivalent, are slightly different from other approved reference biologics but has no clinically significant differences. The firm interacts in these fields, either directly or indirectly, by the buying and selling of intellectual property and other assets relating to generics and biosimilar drugs. The geographic scope of these investment can fall either domestically or internationally.
Contact
IPO
Employees
Officers
The intrinsic value of one SDZ stock under the Base Case scenario is 43.65 CHF.
Compared to the current market price of 40.6 CHF, Sandoz Group AG is Undervalued by 7%.